ADVISORY, Sept. 22, 2014 (GLOBE NEWSWIRE) --
Fibrocell Science, Inc. (Nasdaq:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases, will visit the NASDAQ MarketSite in Times Square.
In honor of the occasion, David Pernock, Chairman and Chief Executive Officer will ring the Opening Bell.
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Tuesday, September 23, 2014 – 9:15 a.m. to 9:30 a.m. ET
Fibrocell Science, Inc. Investor Contact:
S.A. Noonan Communications, LLC
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq.
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.
For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/.
A webcast of the NASDAQ Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx.
To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.
About Fibrocell Science, Inc. (Nasdaq:FCSC):
Fibrocell Science, Inc. (Nasdaq:FCSC) is an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's lead orphan drug program is in late-stage pre-clinical development for the treatment of RDEB (recessive dystrophic epidermolysis bullosa). Working in collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is genetically modifying autologous fibroblast cells to express target proteins that are inactive or missing from patients with rare genetic skin and connective tissue disorders. Fibrocell is also pursuing medical applications for azficel-T—the Company's proprietary autologous fibroblast technology—for restrictive burn scarring and vocal cord scarring. Both indications are currently in Phase II clinical trials. For additional information, visit www.fibrocellscience.com.
About NASDAQ OMX Group
NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.